Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects.
about
Marijuana: current concepts(†)Regulation of nausea and vomiting by cannabinoids and the endocannabinoid systemThe role of cannabinoids in regulation of nausea and vomiting, and visceral pain.Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial.Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia.Nonsmoker Exposure to Secondhand Cannabis Smoke. III. Oral Fluid and Blood Drug Concentrations and Corresponding Subjective Effects.Single dose delta-9-tetrahydrocannabinol in chronic pancreatitis patients: analgesic efficacy, pharmacokinetics and tolerability.Pharmacokinetic and pharmacodynamic profile of supratherapeutic oral doses of Δ(9) -THC in cannabis users.Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.The Role of the Endocannabinoid System in the Brain-Gut Axis.Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics.Mechanisms contributing to cognitive deficits in cannabis users.Effects of tetrahydrocannabinol on balance and gait in patients with dementia: A randomised controlled crossover trial.A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics.A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders.Exogenous Cannabinoid Efficacy: Merely a Pharmacokinetic Interaction?Cannabinoids: from pot to lab
P2860
Q21090461-1D22B332-0BA7-4997-9659-BBBAD26226DBQ28301264-0BC5112A-867D-47EC-BB72-9C9891DCF2B8Q34464535-B7C3B825-F9DD-4FF1-8580-A8E4CEF968D6Q35730949-5803ABE1-1F18-40AE-A0C4-8FC19BE69E5FQ35781874-EB29CD0B-3E55-4656-99F2-45424BA05E6EQ36232377-6FAC1A60-9E04-47ED-96B4-3BE3C81C8695Q36618089-6E1B0B5B-1130-43DD-9598-B314790890C5Q36951509-21459075-6260-4097-A9DF-251BA5C69F5CQ38212376-DC11B697-BF7F-44C0-8F13-5677584452B2Q38822341-C4828D30-BE76-4618-8CBD-E8A7534DAAE0Q39113008-79A8747F-E1B0-42B8-8C7C-DDFF7DA0F573Q39245794-89AD1FD0-A858-4322-B629-9A75A5D3C335Q39395073-883002EC-0115-4060-9024-008814F694B8Q41537590-AF2DAE47-C249-44FF-9575-1E8B758BC0BDQ47101767-3DBE8CA2-3566-42A6-8EDC-DF8ECB27E77BQ47787065-2FD3FF5C-FF35-4CBE-A2D0-A75315EB8C0EQ57135034-ED181014-3447-4FBC-BBFE-D319EF95B93C
P2860
Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Novel Δ(9) -tetrahydrocannabin ...... ising pharmacodynamic effects.
@ast
Novel Δ(9) -tetrahydrocannabin ...... ising pharmacodynamic effects.
@en
type
label
Novel Δ(9) -tetrahydrocannabin ...... ising pharmacodynamic effects.
@ast
Novel Δ(9) -tetrahydrocannabin ...... ising pharmacodynamic effects.
@en
prefLabel
Novel Δ(9) -tetrahydrocannabin ...... ising pharmacodynamic effects.
@ast
Novel Δ(9) -tetrahydrocannabin ...... ising pharmacodynamic effects.
@en
P2093
P2860
P50
P1476
Novel Δ(9) -tetrahydrocannabin ...... mising pharmacodynamic effects
@en
P2093
Astrid Lipplaa
Jan I Freijer
Joop M A van Gerven
Lennard B Karger
Marieke L de Kam
Tim L Beumer
P2860
P356
10.1111/J.1365-2125.2012.04164.X
P407
P577
2012-07-01T00:00:00Z